Skinvisible, Inc. (SKVI): Operating Cash Flow
-$38.4K
Year ended 2025-12-31
$3.8K
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$38.4K | n/m | 2026-03-31, From 2025-01-01 |
| 2024-12-31 | -$69.8K | n/m | 2026-03-31, From 2024-01-01 |
| 2023-12-31 | -$77.2K | n/m | 2025-04-14, From 2023-01-01 |
| 2022-12-31 | $45.2K | -87.9% | 2024-04-16, From 2022-01-01 |
| 2021-12-31 | $374.6K | +718.5% | 2023-03-30, From 2021-01-01 |
| 2020-12-31 | $45.8K | n/m | 2022-03-31, From 2020-01-01 |
| 2019-12-31 | -$128.2K | n/m | 2021-04-15, From 2019-01-01 |
| 2018-12-31 | -$34.3K | n/m | 2019-04-15, From 2018-01-01 |
| 2017-12-31 | -$13.9K | n/m | 2019-04-15, From 2017-01-01 |
| 2016-12-31 | -$244.4K | n/m | 2018-03-23, From 2016-01-01 |
| 2015-12-31 | -$852.7K | n/m | 2017-04-17, From 2015-01-01 |
| 2014-12-31 | -$1.17M | n/m | 2016-04-14, From 2014-01-01 |
| 2013-12-31 | -$751.7K | n/m | 2015-03-31, From 2013-01-01 |
| 2012-12-31 | -$538.9K | n/m | 2014-04-11, From 2012-01-01 |
| 2011-12-31 | -$192.5K | n/m | 2013-04-16, From 2011-01-01 |
| 2010-12-31 | $17.3K | n/a | 2012-11-19, From 2010-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Skinvisible, Inc. (SKVI) | 2025-12-31 | -$38.4K | n/m |
| Jupiter Neurosciences, Inc. (JUNS) | 2025-12-31 | -$5.41M | n/m |
| Bioadaptives, Inc. (BDPT) | 2025-12-31 | -$516.0K | n/m |
| PRF Technologies Ltd. (PRFX) | 2025-12-31 | -$3.96M | n/m |
| Talphera, Inc. (TLPH) | 2025-12-31 | -$11.36M | n/m |
| Impact Biomedical Inc. (IBO) | 2025-12-31 | -$1.89M | n/m |
| Lyell Immunopharma, Inc. (LYEL) | 2025-12-31 | -$150.02M | n/m |
| Neonc Technologies Holdings, Inc. (NTHI) | 2025-12-31 | -$20.36M | n/m |
| Altimmune, Inc. (ALT) | 2025-12-31 | -$67.53M | n/m |
Compare SKVI, JUNS, BDPT, PRFX side by side · Screen every company in Pharmaceutical Preparations ↗